Key Highlights
- Carta Healthcare acquires Realyze Intelligence to enhance its AI capabilities and drive clinical trial matching.
- Realyze Intelligence’s AI technology identifies patients for trials in seconds, improving oncology outcomes.
- Combined platforms reduce labor demands for clinical data abstraction and research while enhancing trial feasibility.
- UPMC Hillman Cancer Center saw 7x more patients matched to trials using Realyze Intelligence.
- Focus on cancer research addresses urgent global needs with advanced data automation and analysis.
Source: PR Newswire
Notable Quotes
- “We believe data is the single most important ingredient to improve healthcare. We are inspired by Realyze Intelligence’s shared ability to maximize insights from clinical data for clinical trials and cancer registries.” — Brent Dover, CEO at Carta Healthcare
- “High-quality, timely data is essential for identifying eligible patients, yet much of it remains trapped in EHRs. We are excited to revolutionize clinical trial matching and improve outcomes with Carta Healthcare.” — Aaron Brauser, Founder and CEO at Realyze Intelligence
SoHC's Take
The acquisition of Realyze Intelligence positions Carta Healthcare as a leader in leveraging AI to address critical challenges in healthcare research and clinical data abstraction. This integration brings significant value to oncology research, where trial participation remains critically low. By automating patient identification and reducing the labor-intensive processes tied to unstructured data in EHRs, the combined technology can enable faster clinical advancements and improve patient outcomes. With cancer research as a focal point, this collaboration underscores the growing role of AI in healthcare innovation and transformation.
